Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Stock analysts at Brookline Capital Markets issued their Q2 2026 EPS estimates for Candel Therapeutics in a research report issued to clients and investors on Sunday, May 17th. Brookline Capital Markets analyst K. Dolliver expects that the company will earn ($0.26) per share for the quarter. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.11) EPS.
Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They set an “overweight” rating for the company. Citigroup reduced their target price on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, March 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.00.
Candel Therapeutics Stock Down 3.0%
Shares of CADL stock opened at $7.66 on Wednesday. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $9.27. The firm’s fifty day moving average price is $6.03 and its two-hundred day moving average price is $5.65. The firm has a market capitalization of $561.25 million, a P/E ratio of -7.82 and a beta of -0.59.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.16.
Insider Activity at Candel Therapeutics
In related news, Director Paul B. Manning purchased 550,458 shares of Candel Therapeutics stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $5.45 per share, for a total transaction of $2,999,996.10. Following the transaction, the director owned 2,763,527 shares of the company’s stock, valued at approximately $15,061,222.15. This represents a 24.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 14.30% of the company’s stock.
Institutional Investors Weigh In On Candel Therapeutics
A number of institutional investors have recently modified their holdings of CADL. Vanguard Group Inc. boosted its stake in shares of Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares during the last quarter. Geode Capital Management LLC raised its holdings in Candel Therapeutics by 31.5% during the second quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock worth $4,575,000 after buying an additional 216,509 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Candel Therapeutics during the first quarter worth $845,000. Halter Ferguson Financial Inc. raised its holdings in Candel Therapeutics by 20.9% during the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after buying an additional 155,996 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Candel Therapeutics in the third quarter valued at about $697,000. 13.93% of the stock is owned by institutional investors.
Candel Therapeutics News Summary
Here are the key news stories impacting Candel Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its 2026 EPS estimates for Candel Therapeutics, trimming expected losses for the year to ($0.85) from ($1.03), and also improved forecasts for Q2, Q3, and Q4 2026. HC Wainwright estimate update
- Positive Sentiment: The same firm also boosted longer-term estimates for FY2027 to $0.35 per share, signaling a more bullish outlook for profitability later in the pipeline. HC Wainwright long-term estimate update
- Positive Sentiment: Brookline Capital Markets also published estimates that were broadly constructive, with FY2026 EPS projected at ($1.11) and quarterly losses narrowing into year-end. Brookline Capital Markets estimate update
- Neutral Sentiment: A Zacks note highlighted that analysts’ mean price target implies roughly 148.5% upside, which may be reinforcing speculative interest in the stock. Zacks article on analyst upside
Candel Therapeutics Company Profile
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
